Rationale: Only a small portion of the known heritability of cardiovascular diseases, such as heart failure, can be explained based on single-gene mutations. Chromatin structure and regulation provide a substrate through which genetic differences in noncoding regions may affect cellular function and response to disease, but the mechanisms are unknown.
C
ommon heart failure has a large heritable component 1 ; however, few individual causal gene mutations have been revealed. 2 In addition to the role of multiple rare variants, 3 another possible mechanism contributing to the heritability of heart failure is epigenetic modification, which controls genomic structure and gene expression in a cell type-specific manner. 4, 5 DNA methylation is the covalent addition of a methyl group to the 5′ carbon of cytosine nucleotides. Previous studies have shown that DNA methylation contributes to normal development in plants and animals by influencing gene expression. 6 Traditionally, DNA methylation is thought to be a marker of heterochromatin because condensed chromatin has a higher level of DNA methylation, for example, as observed during X-chromosome inactivation. More recently, it has been suggested that the effect of DNA methylation on gene expression is context dependent, with promoter/transcription start site methylation being associated with silencing and gene body methylation associated with activation. 7 Unlike other
The role of DNA methylation in other common diseases, such as cardiovascular disease, is less well understood. Recent studies using human samples have discovered changes in DNA methylation in the setting of heart diseases. [15] [16] [17] [18] These investigations open a new avenue of research into regulation of cardiac physiology and disease, but there are several unanswered questions. First, human studies lack a case-control format to precisely determine the effects of the environment and rule out other comorbid conditions that are pervasive with human heart failure and potentially undetected. Second, most studies in the heart have not used methods to give single-base resolution for the analysis of DNA methylation, which precludes determination of the genomic loci (be they coding or noncoding) under regulation by the modification. Finally, human studies lack the ability to control for genetic variability, which can be a confounding factor in determining the role of chromatin modifications. 19 To overcome these limitations, we have carried out what we think to be a first of its kind study in cardiovascular epigenomics: mouse strains that are either susceptible (BALB/cJ) or resistant (BUB/BnJ) to isoproterenol-induced heart failure were administered the β-adrenergic receptor agonist followed by genomewide bisulfite sequencing to measure DNA methylation. Because these mice are inbred and have fully characterized genetic diversity (ie, their polymorphisms are known) and environmental conditions are constant, this approach enables investigation of the effects of DNA methylation on disease phenotype in a pure manner. Our study has several major findings: the DNA methylome in the mouse heart is characterized for the first time with single-base resolution; genetic differences play a large role in basal DNA methylation differences between strains; DNA methylation seems to coordinate with histone-based chromatin marks; and, most importantly, DNA methylation is predictive of susceptibility to heart failure before exposure to disease-inducing stress.
Methods
Detailed Methods section is available in the online-only Data Supplement.
Results

Measurement of Cardiac CpG Methylation With Single-Base Resolution by Reduced Representational Bisulfite Sequencing
Results on sequencing depth and alignment are provided in Table 1 . Given the size of the mouse genome (≈2.65 billion bp), ≈265 million uniquely aligned 100-bp reads would be needed to achieve a 10-fold coverage of the entire genome using traditional shotgun sequencing. To lower the sequencing demand and data size while maintaining data quality, we used reduced representational bisulfite sequencing (RRBS) instead of shotgun sequencing. This method enabled high coverage of the CpGs within RRBS libraries (Table 1) , allowing for confident assignment of methylation status.
The restriction endonuclease MspI, which recognizes the CCGG motif and generates a CGG sticky end, was used to digest genomic DNA into fragments during library preparation. To quantify how this step affects CpG measurement, we compared the annotation of CpG sites covered by our RRBS libraries with the total CpGs in the reference genome. Figure 1 shows the location of CpGs covered by our RRBS libraries compared with all the CpGs in the mouse genome. If one looks at these CpGs on the basis of localization in promoter, exon, intron, or intergenic regions, it is apparent that CpGs are naturally enriched in coding regions (compare Figure 1B with Figure 1A ). This enrichment is further accentuated by the RRBS measurements (compare Figure 1C with Figure 1B ; this step, therefore, may influence the portion of the methylome examined in our RRBS studies but is consistent with that observed by other studies 20 ) . Figure 1D to 1F further demonstrate that our measurements enrich for detection of CpGs in and around CpG islands, which are thought to be sites of dynamic regulation by methylation. The CpG islands are also preferentially demethylated when compared with other regions of the genome ( Figure 1G ); yet all regions we sampled in the heart demonstrate a bimodal distribution. This distribution may be different from other cells/tissues. For example, Jiang et al 21 reported a global hypermethylation in oocytes and sperms from zebrafish. When examining the degree of methylation in a nonbinary manner according to genomic elements, it is apparent that of the genomic regions with <5% methylation, most occur in CpG islands and shores ( Figure 1G , inset), whereas the genomic regions methylated >80% of the time tend to distribute according to the functional annotation of genome and do not enrich around islands or shores. Most CpGs outside of any CpG islands (lone CpGs) are hypermethylated. These observations were true for both mouse strains and were not fundamentally altered by isoproterenol treatment. In our datasets, the methylation characteristic (ie, methylated or not methylated) of a given CpG in a fragment tends to be conserved-that is, if one CpG on a fragment is methylated, the other ones present on the same fragment tend also to be methylated and vice versa. We, therefore, present all the forthcoming data analyses on a per-fragment basis to reduce the complexity of the data. All single-base resolution data are available in the online-only Data Supplement.
DNA Methylation Varies Genetically and Is Affected by Isoproterenol Treatment
As part of a comprehensive phenotyping study on multiple mouse strains-the results of which were published 22 while this article was under review-we determined the inbred mouse strains BALB/cJ and BUB/BnJ to be susceptible and resistant to isoproterenol-induced cardiac remodeling, respectively. BALB/cJ mice develop left ventricular chamber
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March 4, 2016 dilation ( Figure 2C and 2D) 3 weeks after isoproterenol pump implantation, commensurate with a modest decrease in ejection fraction ( Figure 2A ) and substantial hypertrophy Figure 2B . BUB/BnJ mice, in contrast, are largely resistant to these changes (with the exception of increased LV volume in diastole; Figure 2C ). Although the strains did not exhibit significant differences in ejection fraction (Figure 2A ), it is noteworthy that these measurements were made when the animals were still under constant β-adrenergic stimulation because of the isoproterenol pump. Furthermore, we cannot totally rule out that the effects of the surgery or pump implantation affected CpG methylation; however, as discussed below, the conspicuous enrichment of differentially methylated fragments (DMFs) in cardiac genes, combined with the 3-week period between pump implantation and experiment, mitigates this concern. Although individual CpG methylation status is necessary to understand locus-specific regulation, recent studies have shown that segments of DNA tend to exhibit similar methylation status when one examines several hundred bases-the size scale of the MspI-digested fragments sequenced in this study. To explore this phenomenon, we binned our methylation measurements according to MspI fragments and plotted behavior per fragment in Figure 2E to 2J. Although the majority of MspI sites had no substantial methylation difference between strains, a surprising number of CpGs exhibited markedly different methylation status, that is, they were methylated in one strain and not the other at baseline (Figure 2G and 2J; cytosines that were variable between the 2 strains [ie, cytosine in one strain and another base in the other strain] were omitted from this analysis). In contrast, the number of DNA fragments modified after 3 weeks of isoproterenol treatment is small in each strain, as shown in Figure 2E and 2F. As expected, the trends were similar to what is observed with individual CpG analyses (Online Figure IA and IB), with the caveat that the differences between strains and following treatment are muted by the fragment-binning step. An advantage of analyzing on the basis of fragments, however, is that one gains a further buffer against experimental variability (ie, a CpG being modified in one experiment and not another) while increasing Figure 2H and 2I), most CpGs did not change with statistical significance after isoproterenol treatment. However, a reproducible subset of fragments (red spots) were increased or decreased in methylation after the drug. To test whether genomic variances contribute to the basal difference of DNA methylation between 2 strains, we calculated the percentage of DNA fragments with or without singlenucleotide polymorphisms (SNPs). After removing all CpG dinucleotides whose cytosines overlap with known or imputed SNPs, we found that although in the whole genome, 10.2% (20 590 of 201 515) of non-differentially methylated DNA fragments have at least 1 SNP, this ratio increased to 41.1% (789 of 1919) when DNA fragments with different basal methylation levels between 2 strains were considered ( Figure 2K ; in contrast to the analyses elsewhere, this SNP analysis in Figure 2K refers to variable bases anywhere in the fragment; as described above, whenever the base varied between strains, it was thrown out for consideration of methylation status at that residue). This result demonstrates that DNA fragments with SNPs are more likely to have different DNA methylation levels.
Principal component analyses were also used to investigate the reproducibility of the methylation measurements and to interrogate the relationship between genetics and DNA methylation. Figure 2L shows that strains grouped together according to the first 3 principal components. These findings reflect that genetic background plays a significant role in determining the DNA methylome. Finally, a preferential demethylation was observed after isoproterenol in both strains especially in BUB/BnJ (Figure 3A-3H; Online Table I ). The regions affected by isoproterenol treatment seemed to cluster, with these clusters then distributed across the genome, occurring on all chromosomes with a slight preference on chromosome 5 and reduction on chromosome X (Figure 3A and 3B; because female mice were studied, no data are available for the chromosome Y). To our knowledge, this is the first demonstration that the phenotypic differences observed between these strains may result in part from DNA methylation.
Differential Methylation Target-Specific Genomic Regions and Types of Chromatin Domains
Online Table I shows the DMFs after isoproterenol treatment in the BALB/cJ and BUB/BnJ mice. Among the 337 027 DNA fragments measured in both strains, 1509 of them show differential methylation after isoproterenol treatment in at least 1 strain. Despite the similar volcano plot shape in each strain ( Figure 2H and 2I), the overlap of DMFs between 2 strains is small. Only 31 fragments show uniform behavior in both strains according to our statistical threshold (Table 2 ). To understand the potential function of this differential methylation, we investigated genes associated with DMF(s). Gene Ontology and other functional annotation revealed the genes from the sensitive strain BALB/cJ to be enriched in heart disease-associated functions, whereas genes from the resistant strain BUB/BnJ are involved in abnormal growth and cardiac muscle contractility (Online Table II) .
Previous investigations have suggested that DNA methylation in the promoter region is negatively correlated with gene expression. To test this phenomenon in the heart, we conducted gene expression analyses using microarrays. When examining the methylation of promoters defined by the sum of 500 bp upstream and downstream of the transcription start site for all genes, there is no correlation between DNA methylation and gene expression (Online Figures IIA-IIC and III; these data refer to genes for which we have both expression and CpG methylation data). To explore this relationship in more depth, we subdivided the groups of genes based on their relative expression levels (Online Figure IV) and investigated the DNA methylation profile across the promoter, rather than taking the sum behavior. Interestingly, despite all transcription start sites favoring demethylation, a variable pattern of regulation revealed itself with this analysis ( Figure 4A , 4C, 4E, and 4G): highly expressed genes tended to have less variability in the methylation at the transcription start site (the thick region of the violin plot is compacted toward the bottom in the vertical dimension). Genes with lower expression tended to have greater variability in this region (the thick region extends higher in the violin plot). The same analysis of the gene body also revealed a variable pattern of DNA methylation between genes of difference expression levels, with highly expressed genes having the track of demethylation extend further into the gene body than lowly expressed genes ( Figure 4B , 4D, 4F, and 4H; Online Figure V shows the average behavior around transcription start sites and in gene bodies for all genes measured on the array).
Inspection of the raw DNA methylation data revealed that some CpGs were highly correlated with each other in terms of their changes in methylation after isoproterenol. To quantify this phenomenon across the measured methylome, we calculated the correlation among the top 15 000 DNA fragments with variable methylation and built a weighted network based on the correlation matrix (Online Figure VI) . In this analysis, DNA fragments are grouped in a module when they exhibit similar behaviors and 1 EigenCpG is assigned to each module to represent the group behavior. To show the higher order topology, we correlated the EigenCpG network with the physiological traits after isoproterenol treatment. Interestingly, we found that most modules have some level of correlation with isoproterenol treatment: some modules show a uniform response to isoproterenol treatment in both BALB/cJ and BUB/ BnJ strains, whereas others show a different response between 2 strains (Figure 5 , top; Online Figure VI) . We also found a few modules that, despite no significant responses to isoproterenol treatment, show distinct methylation levels between 2 strains at the basal level indicating methylation polymorphisms between the 2 strains.
Network analysis allowed analysis of interactions between DNA methylation signatures and other chromatin marks. Histone modifications act in a combinatorial manner to specify chromatin states, including transcriptional outcomes. To determine the relationship between the above DNA methylation modules and chromatin states, we investigated the presence of known cardiac protein-level features revealed by chromatin immunoprecipitation and DNA sequencing and deposited in ENCODE. To rule out the possibility that some chromatin marks favor CpG rich regions independent of methylation status, we chose the set of 15k DNA fragments used for network construction (rather than the whole genome) as the background to calculate the P value for the overlap among these subsets of loci. Surprisingly, we observed ( Figure 5 ) modularity within the heatmap according to both cardiac epigenome track direction (row wise) and the DNA methylation module direction (column wise). Moreover, we found that most of DNA methylation modules that exhibit a decrease of methylation after isoproterenol treatment overlap with H3K4me1 tracks, suggesting that these epigenetic marks may coordinately regulate cardiac gene expression.
To move beyond the correlative nature of these chromatin associations, we next sought to further examine the mechanisms through which DNA methylation may alter cardiac signaling networks. We hypothesized that despite the fact that the pattern of DNA methylation in and around transcription start sites was similar across genes, strain-specific epigenetic regulation may operate by differential targeting of transcription factor motifs. Interestingly, although the group of transcription factors regulated by methylation was similar, the 2 strains showed different preference for the transcription factors whose target genes were most enriched for altered methylation (Online Table III ; significance values compare enrichment of transcription factor-binding motifs in the differentially methylated subset versus enrichment across the entire genome; only those factors with significant P values, expressed as -log, are shown): for instance, BUB/bnJ had preferential targeting of E2F-4 signaling, whereas BALB/cJ showed greater regulation of early growth response 1 (Egr-1) targets. As a transcriptional repressor, 23 E2F-4 would be expected to normally inhibit cell cycle/proliferative genes, whereas the Egr-1 family has been recently implicated in cardiac pathologies, including hypertrophy, 24 although the mechanisms by which these factors choose their genomic targets are incompletely understood. Previous studies had implicated histone regulation 25 in altering transcription factor targeting, but this is the first evidence, to our knowledge, that either of these transcription factors is regulated by DNA modification. Future experiments will be required to determine whether, and by what mechanisms, DNA methylation alters transcription factor binding.
Next, we examined whether differentially methylated genes constituted a subnetwork that may functionally interact in vivo. Ingenuity Pathway Analysis was used to interrogate relationships among genes from both strains with altered promoter methylation after isoproterenol treatment, revealing a cardiac interactome that is highly connected based on known experimental literature ( Figure 6 , cardiac interactome data used; note that when the total interactome is used without reference to cell type, the sampled subnetwork loses its structure and becomes dominated by a massive hub; Online Figure  VIII) . Interestingly, this subnetwork is populated with nodes regulated in both strains, as well as those regulated in only 1 strain, implying that the effects of the methylation machinery at the level of the genome are coordinated with the ultimate protein interaction networks; yet this coordination, while having the potential to alter the flow of information through the network, does not change its structure. Finally, we asked the question whether regions of genetic variation, shown in our recent study to associate with cardiac traits across the hybrid mouse diversity panel, were also host to dynamic regulation by DNA methylation. As shown in Online Table IV, genome-wide association study (GWAS) hits (ie, genes where variation correlated with a heart failure phenotype by a GWAS 22 ) exhibited alterations in DNA methylation, with an apparent preference for demethylation in these regions that was significant for BALB/ cJ (P value based on binomial distribution of 0.016) but not for BUB/bnJ (P=0.618), likely due to a more pronounced overall hypomethylation in the latter strain. These findings further support the intriguing possibility that epigenetic variation in the form of DNA methylation may also contribute to the altered traits observed across the hybrid mouse diversity panel.
Discussion
Genetic differences between inbred mouse strains have been shown to contribute to various cardiac 26 and other 27 phenotypes, although the role of common genetic variation in cardiac hypertrophy and failure is unknown. Furthermore, the mechanisms through which common variation predisposes for or against heart disease have not been explored in the context of chromatin. Our study provides the first cardiac epigenomic analysis of DNA methylation between individuals with fully characterized (and stable) genetic differences: the data demonstrate, with single-base resolution, variations in basal DNA methylation between mouse strains before stress that correlate the phenotypic response to isoproterenol. These investigations significantly advance our understanding of how the cardiac epigenome may integrate genetic and environmental signals. These studies also have fundamental implications for disease prediction.
How might the differences in methylation alter subcellular processes to produce a differential phenotypic response to isoproterenol? Our studies do not support dynamic alteration of promoter methylation as a pervasive mechanism of gene regulation in hypertrophy (in cis), although effects of DNA methylation in trans are certainly possible within and between chromosomes. CpGs with distinct methylation status may contribute to altered functionality of enhancers, thereby influencing transcription indirectly. In general, we posit that the altered DNA methylation landscape leads to a global shift in chromatin accessibility, such that the plasticity of the genome differs in a heritable way, thereby affecting phenotype. We have no evidence for altered expression of DNAmethylating/demethylating enzymes between these strains, but the possibility exists that SNPs in genes for proteins that participate in DNA methylation and its reading (eg, transcription factors that use methylated DNA as a cue for binding) may result in altered transcript and protein expression, thereby altering the DNA methylome between strains. Another potential mechanism involves altered chromatin accessibility at specific loci associated with response to stress. In this model, the susceptible and resistant strains would respond differently to isoproterenol-induced gene expression because the signaling pathways activated by the drug would impinge on a genome with different propensity to pathological gene expression in one mouse versus another. This conjecture clearly requires further experimental evidence, including (1) evaluation of whether the DNA methylome differences in the hearts of these strains are the same differences observed in other organs; (2) whether the correlation between DNA methylation and heart failure phenotypes is robust across multiple genetic backgrounds; and (3) whether DNA methylation differences lead to altered protein binding.
Despite recent studies using patient samples [15] [16] [17] [18] and pigs, 28 ,29 the molecular mechanisms by which altered DNA methylation contributes to the progression of cardiomyopathy . Functional annotation reveals mechanisms linking differential methylation after isoproterenol (ISO) to cardiac phenotype. Cardiac-specific pathways were examined for enrichment in differentially methylated genes using Ingenuity Pathway Analysis, revealing cardiac development to be physiological process most targeted by differential methylation after ISO. Interestingly, several known cardiac genes underwent altered regulation, allowing relationships among the signaling network to be mapped. Red nodes are differentially methylated only in BALB/cJ, green nodes only in BUB/BnJ, orange nodes in both, and white nodes in neither. disease; yet, they are limited because of the genetic, environmental, and disease heterogeneity of human samples. Our study used a strict case-control experimental design, including consistent housing conditions and diet. Furthermore, the genome-wide RRBS method we used here samples randomly from the entire mouse genome, providing more information than a microarray-based method that measures only promoter regions. Previous studies of mouse genetics focused on how to explain strain specificity through genetic variation, 27 and such studies are similar to GWASs in humans. It is also likely that DNA methylation acts as an amplifier of the effects of primary DNA sequence differences. 30 DNA methylation polymorphism is highly dependent on genetic polymorphism. 31 One piece of evidence for this is that the F1 hybrids of 2 different strains maintain the strain-specific methylation pattern from their parental allele. 32 Functional annotation of regions associated with altered DNA methylation after isoproterenol treatment identified different pathways in the susceptible and resistant strains. For example, when studying the DNA regions with upregulated methylation after isoproterenol, we found genes associated with heart weight and size enriched in the BALB/cJ mice, whereas muscle contractility-associated genes were enriched in the pool of genes with increased methylation in the BUB/BnJ mice. While this study was under review, a similar GWAS using the same experimental model of isoproterenol-induced cardiac pathology in mice was published, identifying several candidate loci controlling cardiac mass and fibrosis. 22 Whether variation in DNA methylation similarly associates with clinical traits of heart disease in a GWAS approach will require further investigation, as will the question of how genetic and epigenetic variation interact in a genome-wide manner.
For a single gene, whether and how DNA methylation regulates its expression depend on the combination of many factors, including histone modifications, binding of transcription factors, and higher order chromatin structure. A study of DNA methylation and gene expression levels in human blood cells reported that although some modules are highly correlated (in a positive or negative manner) with gene expression, most modules had no correlation between gene expression and DNA methylation. 33 A recent study of human placenta indicates that the relationship between DNA methylation and gene expression is highly dependent on the type of gene (ie, its function in the cell type of interest) and the region in the gene where the methylation occurs. 34 One interpretation of the data in Figure 4A , 4C, 4E, and 4G is that demethylation of promoters alone does not silence genes (hence the variability in the silenced genes), and other protein-dependent mechanisms are necessary, whereas demethylation is invariably required for high gene expression. This may also explain the greater variability in demethylated gene bodies seen in highly, contrasted with lowly, expressed genes in Figure 4B , 4D, 4F, and 4H.
The traditional method of identifying DMFs using a statistical hypothesis test is based on the assumption that all methylation measurements are independent and identically distributed. However, this strong assumption does not account for the reality of biological networks, in which codependency of interactions and combinatorial specification are common occurrences. To account for this biological phenomenon, we used DNA fragments to build a comethylation network, thus circumventing the difficulty that some DNA fragments are located in enhancers or other functional element regions far away from known genes. Next, we built an epigenetic interaction network in the heart, showing that DNA fragments can be clustered into modules, that is, groups of CpG-containing fragments with similar regulation features across multiple samples and experimental conditions (the modularity in the DNA methylation [column wise, Figure 5 ] cannot be explained by the membership of DNA fragments in multiple modules because each DNA fragment was assigned to only 1 DNA methylation module, disallowing overlap). An implication of this clustering is that the principles underlying regulation of these loci are shared: fragments that exhibit similar dynamics in terms of DNA methylation are predicted to reflect similar chromatin remodeling and transcriptional regulatory mechanisms at these loci. Interestingly, members within the same methylation module can be located far away from each other in the linear position of one chromosome or even located on different chromosomes. We interpret this to indicate hierarchical regulation by epigenetic machinery, rather than progressive actions along a chromosome. It is interesting to speculate that regions in the same DNA methylation module are positioned proximally in 3-dimensional space although additional experiments would be required to test this conjecture.
Our study also revealed that chromosomal regions with similar DNA methylation changes after isoproterenol stimulation share a common pattern of epigenetic marks. In addition to the aforementioned modularity in the DNA methylation measurements, Figure 5 demonstrates clustering of the epigenome tracks (ie, protein marks; row wise in Figure 5 ), which may be the result of correlation between the different epigenetic marks or because of the correlation with DNA methylation. Because DNA modules are ordered based on their correlation with isoproterenol treatment, the observation of epigenomic clustering indicates that if the DNA methylation patterns of 2 genomic regions respond to the environment in a similar way, these 2 regions may also have a similar histone modification pattern. An open question is the temporal relationship between DNA methylation and epigenomic protein marks at individual loci.
The observation that transcription factor-binding motifs are differentially targeted by methylation in the 2 strains provides a potential mechanism that spans individual locus to entire genome: by altering methylation and thereby transcription factor binding, evolution can tailor the transcriptome and its response to stress on a global level. Although additional experiments will confirm or deny this hypothesis, as with protein-based chromatin signatures, a DNA methylation mechanism at the level of transcription factor binding could explain coordination across multiple loci, enabling rapid, coordinated transcriptional responses tuned by epigenetic programming. To validate our observations in the context of the known cardiac interactome, we additionally examined the
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March 4, 2016 subnetwork defined by the differentially methylated genes after isoproterenol. Interestingly, the pathological stressor engaged methylation to regulate a highly connected group of molecules, with strain-specific differences emerging with regard to which nodes were altered. These findings suggest that the proteome-level networks in heart failure are regulated in part by epigenetic factors, such as DNA methylation, and that genetic variation influences gene expression and, by virtue of differentially targeting specific nodes, potentially the flow of information through protein networks. These observation can be further explored in a larger cohort of genetically variable individuals-like the hybrid mouse diversity panel or a human population-which would further test the relationship among the protein network and the role of DNA methylation and genetics to modulate this network in the setting of pathological stimulation.
There are some limitations with the isoproterenol model used in this study, namely that it recapitulates only part of the complex syndrome of heart failure in humans, which is the sequela of genetic risk compounded by environmental factors, such as ischemia, stress, toxicity, neural hormonal imbalance, and hypertension. We chose this model because we had data on how isoproterenol differentially affects cardiac phenotype and gene expression in a large panel of inbred mice 22 and because it is a unitary, well-defined stressor that is relatively operator independent (as opposed to infarction or pressure overload). The presence of the isoproterenol pump throughout the experiment means that the animals are receiving constant β-adrenergic stimulation. In the strains we examined, ejection fraction was different between them but depressed in neither after isoproterenol treatment, suggesting that we are studying a form of cardiac pathology that has not progressed to failure according to clinical measurements. It is noteworthy that the ejection fraction and fetal gene expression measurements in these mice fall in different ends of the spectrum in terms of genetic susceptibility to disease (Online Figures VI and VII) . The timing of analysis is also likely contributory to the DNA methylome features: in addition to the changes induced by isoproterenol infusion, alterations in methylation may also be influenced by the compensatory actions of the heart (and indeed the entire organism) to the enhanced β-adrenergic state.
To understand how our findings from mice may have clinical relevance, we need to consider DNA methylation in the context of endogenous regulation. The difference in DNA methylation observed in this study may come from noncardiac cells that infiltrate the heart during stress and certainly from noncardiomyocytes, which makes up ≥50%of the mammalian heart by some estimates. 35, 36 Sorting this out is difficult and will require further studies; yet our work clearly shows that there is a different epigenomic signature associated with heart failure susceptibility and resistance, which is the first time such an observation has been reported. Chromatin modifications are also known to be regulated by cellular metabolites. Previous studies have found that cardiac metabolism is aberrant in disease. This includes S-adenosylhomocysteine/Sadenosylmethionine ratio imbalance, as indicated by hyperhomocysteinemia in cardiovascular disease, 37 and accumulation of β-ketoglutarate or 2-oxoglutarate because of inactivation of ketoglutarate dehydrogenase caused by abnormal mitochondrial function and oxidative stress. 38 Previous studies of heart failure metabolism mainly focused on how metabolites impair normal cellular functions, such as mitochondrial function or cell signaling pathways. In view of those studies showing the involvement of SAH/SAM 39, 40 and β-ketoglutarate 41 in DNA methylation, it is possible that metabolic dysfunction in heart failure may alter the epigenome directly. Interestingly, a recent DNA methylation study from the liver 20 used a program called glmnet to predict liver phenotypes based on a subset of CpG methylation events. In principle, a similar approach could be taken, based on the proof of concept in this study and a larger population of genetically variable subjects, to explore the role of DNA methylation to serve as a biomarker for heart failure susceptibility.
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What New Information Does This Article Contribute?
• Genome-wide analyses of DNA methylation provide single-base resolution of this epigenomic mark in the adult heart. • Analyses of multiple strains of mice, with distinct phenotypic responses to the adrenergic agonist isoproterenol, show that DNA methylation presages cardiac pathogenesis.
• Transcriptome analyses conducted in parallel reveal the relationship between DNA methylation and gene expression in the mouse heart and the mechanisms by which this epigenetic mark controls transcriptional networks.
The relationship between epigenetic marks and gene expression during the onset of heart disease is poorly understood. Likewise, there is a need for molecular diagnostics for noncongenital forms of heart failure that would enable differential treatment. Therefore, we undertook a novel epigenomic study in which DNA methylation was measured by bisulfite sequencing in the hearts of mice subjected to isoproterenol stimulation. Our findings reveal differential patterns of DNA methylation in the promoters versus the bodies of genes and demonstrate that highly expressed genes have distinct DNA methylation features from genes expressed at low levels. We also found that DNA methylation marks discriminate a heart failure--susceptible mouse strain from a resistant one before the administration of isoproterenol, suggesting that DNA methylation may be a potential biomarker for disease stratification and might be useful in predicting the severity of disease pathogenesis in humans.
METHODS
Mice
Adult female BALB/cJ or BUB/BnJ mice aged 8---10 weeks were obtained from Jackson Laboratories (Bar Harbor, ME). All protocols involving animals were approved by the UCLA Animal
Research Committee. Mice were housed in pathogen---free conditions according to NIH guidelines.
These mouse strains were chosen based on preliminary studies indicating their susceptibility (BALB/cJ) or resistance (BUB/BnJ) to ISO---induced heart failure relative to ~100 other strains examined in our large scale study (to be published elsewhere).
Isoproterenol treatment
The treatment protocol was adapted from previous studies using the Hybrid Mouse Diversity
Panel to examine phenotypic diversity 1 and isoproterenol (ISO) to induce heart hypertrophy and failure. 2 Briefly, mice were implanted with an Alzet (Cupertino, CA) Micro---Osmotic Pump (Model 1004) filled with 420 mg/kg body weight of ISO to provide a constant supply of 30 mg/kg (body weight)/day of ISO; untreated, strain---matched mice were used as control (no mice died in this cohort).
Phenotyping was performed on cohorts of 5---13 mice per group from which 3 mice per group were randomly selected for methylation analyses. Mice were monitored by echocardiography before surgery and at days 7, 14 and 21 after surgery. Mice were sacrificed at day 21 after surgery and left ventricles were harvested for further analysis. This study reports sequencing data from three biological replicates from each mouse strain in each condition. Transcriptome data of left ventricular heart samples with or without ISO treatment were from Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/). Accession numbers used for BALB/cJ, BALB/cJ (ISO), BUB/BnJ and BUB/BnJ (ISO) were GSM1184098, GSM1184099, GSM1184052 and GSM1184053, respectively.
Genomic DNA extraction
Left ventricles were cut into small pieces, put in a tube with 0.7mL Extraction Buffer (50 mM
Tris---Cl pH 8.0, 50 mM EDTA, 100 mM NaCl, 0.5% SDS, 0.5 mg/mL Proteinase K) and incubated at 55°C
overnight. DNA was extracted using Phenol:Chloroform, followed by ethanol precipitation, and dissolved in 150 mL TE buffer (10 mM Tris---Cl pH 8.0, 0.5 mM EDTA).
Bisulfite conversion for reduced representational sequencing
The RRBS method was adapted from other studies. 3, 4 Genomic DNA was digested with MspI overnight at 37°C and purified using Phenol:Chloroform as described above. DNA fragments were end repaired using Klenow DNA polymerase. An excess amount of dATP was added to provide sufficient 
Illumina sequencing and alignment
The RRBS library sequencing and alignment protocol was adapted from a previous publication. 3 Briefly, 100---base Illumina single---end sequencing reads were generated from previously prepared RRBS libraries using Solexa sequencing technology (Illumina HiSeq 2000 sequencers). The reads were aligned to the strain---specific mouse genome (GRCm38/mm10 substituted with strain---specific single---nucleotide polymorphisms or SNPs from the database of Mouse Genomes Project SNP and indel Release Version 4) 5 using BS---Seeker2, allowing up to ten mismatches. Methylation calling was conducted by the script provided in the BS---Seeker2 program and reads not fully converted by bisulfite treatment were removed. Aligned reads from three biological replicates were pooled together. The methylation level for each measured cytosine was calculated as the number of methylated reads divided by the total number of reads. To achieve an accurate estimate of methylation level, we only included cytosines that are covered by at least ten reads (minimum 10× coverage). High read cutoff was also applied to eliminate PCR effects. CpGs having higher coverage than 99.9% percentile of read counts were removed, using filterByCoverage function in methylKit package. 6 Because the methylation occurs almost exclusively in the CpG context, we focused only on those cytosines in CpG dinucleotides. 7 Fragments with a difference of methylation larger than 10% (for within strains, comparing control to ISO treatment) or larger than 20% (when comparing basal differences between two strains) and FDR less than 0.05 were considered as DMFs. These thresholds were chosen based on the overall distribution of DNA methylation difference ( Figure  2H ---J). These thresholds gave us a sufficient number of high confidence DMFs for further analyses (please see Online Table  I for DMF results and accompanying statistics for each sample).
Identification of differentially methylated regions
Co---methylation network analysis
The weighted Gene Co---Expression Network Analysis (WGCNA) package was used for co---methylation network analysis. 8 The rationale of choosing WGCNA package is because it provides a fast and parallelized calculation for correlation measurement and hierarchical clustering 9 . In addition, this approach implements a dynamic dendrogram branch cutting method 10 that automatically identifies optimized clusters of co---regulated genes or, in our case, DNA methylation. To preserve information regarding both correlation and anti---correlation of co---methylation, the similarity of methylation profiles between two fragments is defined as
, where i and j represent the methylation levels of two DNA fragments. To reduce the computational requirement and remove DNA fragments with consistent methylation level among all samples, the top 15,000 DNA fragments with the highest methylation variation among all samples were chosen for co---methylation network construction. To achieve a scale---free topology, a soft---thresholding power of 10 was chosen, resulting in a R 2 of 0.8 as measured by the scale---free topology model linear regression. This R 2 value meets the recommendation from the authors of WGCNA package. 8 In total, we generated 82 clusters with the smallest cluster having 30 DNA fragments.
Chromatin mark enrichment in DNA methylation modules
To call an overlap between a methylated DNA fragment and a chromatin mark, we required at least 50bp overlap between the DNA fragment and the peak of the mark. A binomial test P---value was calculated to assess the significance of overlap between a chromatin mark and methylated DNA fragment. The background was defined as the fraction of a given chromatin mark associated DNA fragments within all 15,000 DNA fragments (please see the method Co---methylation network analysis)
used for the DNA co---methylation network analysis as defined above with WGCNA. To show the gradient of P values on a heatmap, a ceiling of six was set for the -log10 of P value to minimize the effects of extreme P values on heatmap color code (this adjustment does not change the clustering pattern).
Bioinformatics
The mouse reference genome (mm10) was downloaded from UCSC Genome Bioinformatics Site (ftp://hgdownload.cse.ucsc.edu/). The UCSC Genes track from the Genome Browser was used for genome annotation and the CpG islands (cpgIslandExt) track was used for CpG island annotation.
Functional interpretation of differentially methylated fragments was performed using GREAT (3.0.0). 11 Default parameters were used excepted we required a term having a minimum of 5 genes in the genome to be considered. This limits the number of annotation terms ("hypotheses") tested and provides a fairer multiple test correction, according to the documentation of GREAT. ENCODE chromatin immunoprecipitation tracks for histone modifications and other epigenetic marks were downloaded from the ENCODE Project at UCSC. 12 Cardiac specific ChIP---seq data tracks from ENCODE/LICR were used in our analysis. Principal component analysis (PCA) of DNA fragment methylation was conducted using the function prcomp in R with default parameters except the inputs 
